However, in this study of primary CLL cells from idelalisib-resistant patients, the authors showed that drug resistance and constitutive MAPK pathway activation was associated with the acquisition of recurrent mutations in the KRAS, BRAF and MAP2K1 genes[69]. The gene discussed is MAP2K1; the disease is B-cell chronic lymphocytic leukemia.